CIGB2020- ARI elderly contacts |
CIGB500 in healthy volunteers |
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma |
CIMAVax EGF in Lung Cancer in PHC. Phase IV |
CIMAvax-EGF in Bladder cancer |
CIMAvax-EGF in different maintenance schemes |
CIMAvax-EGF in patients at high risk of lung cancer |
CIMAvax-EGF vaccine Predictor Phase IV |
CIMAvax-EGF-Platelets-Adults- Lung Cancer |
CIMAvax-EGF/Lung cancer/Biomarkers/Prospective CT |
CIMAvax-EGF® in metastatic asymptomatic or mildly symptomatic Castration Resistant Prostate Cancer patients. Phase II-III Clinical Trial |
CIMAvax-EGF®-post-COVID19 convalescent with respiratory disorders-adults-Phase II (CORVAXCIM) |
CITOPROT-III |
Clinical evaluation of the effect anti-inflammatory of the extract of Mangifera indica L. (Vimang®) in patients with diagnosis of Bronchial Asthma |
Clinical Trial Heberbiovac HB vaccine Material Reference Batch |
Clinical trial to evaluate the safety, reactogenicity and immunogenicity of the vax-TyVi vaccine in volunteers between 18 and 20 years of age. |
Clinical Trial with the Outer Membrane Vesicles (OMV) Bivalent AW135 Anti meningocóccal Vacccine Candidate |
Clinical trial, phase II, to evaluate rhEGF efficacy and safety at a dose of 25 or 75 micrograms intralesionally in patients with diabetic foot ulcer (Wagner grade 1 or 2). |
Clinical trial, phase II: Evaluation of TheraCIM hR3 MaB combined with chemo- and radio-therapy to treat patients with epithelial tumors in neck of the uterus, stage III. |
Cocoa catabolites |